Welcome to LookChem.com Sign In|Join Free

CAS

  • or

848498-98-6

Post Buying Request

848498-98-6 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

848498-98-6 Usage

General Description

2,6-dichloro-N-methoxy-N-methylisonicotinamide is a chemical compound with the molecular formula C8H8Cl2N2O and a molar mass of 218.07 g/mol. It is a derivative of isonicotinamide and contains two chlorine atoms, one methoxy group, and one methyl group. 2,6-dichloro-N-methoxy-N-methylisonicotinamide is commonly used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. It has also been studied for its potential use as an anti-inflammatory and analgesic agent. Additionally, it may have applications as a precursor in the synthesis of various organic compounds. Its properties and structure make it an important and versatile chemical in the field of organic synthesis and drug development.

Check Digit Verification of cas no

The CAS Registry Mumber 848498-98-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,4,8,4,9 and 8 respectively; the second part has 2 digits, 9 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 848498-98:
(8*8)+(7*4)+(6*8)+(5*4)+(4*9)+(3*8)+(2*9)+(1*8)=246
246 % 10 = 6
So 848498-98-6 is a valid CAS Registry Number.

848498-98-6SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 17, 2017

Revision Date: Aug 17, 2017

1.Identification

1.1 GHS Product identifier

Product name 2,6-dichloro-N-methoxy-N-methylpyridine-4-carboxamide

1.2 Other means of identification

Product number -
Other names 2,6-dichloro-N-methyl-N-methoxy-pyridine-4-carboxamide

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:848498-98-6 SDS

848498-98-6Relevant articles and documents

Design, synthesis and anticancer properties of isocombretapyridines as potent colchicine binding site inhibitors

Shuai, Wen,Li, Xinnan,Li, Wenlong,Xu, Feijie,Lu, Lixue,Yao, Hong,Yang, Limei,Zhu, Huajian,Xu, Shengtao,Zhu, Zheying,Xu, Jinyi

, (2020/04/24)

A series of novel isocombretapyridines were designed and synthesized based on a lead compound isocombretastatin A-4 (isoCA-4) by replacing 3,4,5-trimethoxylphenyl with substituent pyridine nucleus. The MTT assay results showed that compound 20a possessed the most potent activities against all tested cell lines with IC50 values at nanomolar concentration ranges. Moreover, 20a inhibited tubulin polymerization at a micromolar level and also displayed potent anti-vascular activity in vitro. Further mechanistic studies were conducted to demonstrate that compound 20a could bind to the colchicine site of tubulin,and disrupte the cell microtubule networks, induce G2/M phase arrest, promote apoptosis and depolarize mitochondria of K562 cells in a dose-dependent manner. Notably, 20a exhibited more potent tumor growth inhibition activity with 68.7% tumor growth inhibition than that of isoCA-4 in H22 allograft mouse model without apparent toxicity. The present results suggested that compound 20a may serve as a promising potent microtubule-destabilizing agent candidate for the development of therapeutics to treat cancer.

TRI-SUBSTITUTED ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF PI3-KINASE AND AUTOPHAGY PATHWAYS

-

Paragraph 0332; 0333, (2019/11/04)

The present disclosure relates to tri-substituted aryl and heteroaryl derivatives, pharmaceutical compositions containing them, and methods of using them, including methods for modulating autophagy or preventing, reversing, slowing or inhibiting the PI3K-AKT-MTOR pathway, and methods of treating diseases that are associated with autophagy or the PI3K-AKT-MTOR pathway.

Therapeutic agent pcnsl (by machine translation)

-

Paragraph 0109, (2016/10/09)

The present invention provides a malignant lymphoma therapeutic or preventive agent that comprises as the active ingredient a compound represented by general formula [1] as defined by (I) or (II), or a pharmaceutically acceptable salt thereof. [1] (I) X is CH or N; R1 is a halogen; R2 is a halogen, H, a cyano, a group represented by general formula [9], [9] an optionally substituted heteroaryl, or the like; R3 is H or a hydroxyl; R4 is H or an alkyl; and R5 is H or an alkyl. (II) X is -CRA, RA is -CORB, RB is an optionally substituted amino, alkoxy, or saturated cyclic amino group; R1 is a halogen; R2 is H; R3is H or a hydroxy; R4 is H or an alkyl; and R5 is H or an alkyl.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 848498-98-6